Lung Function after Randomization to Metformin, Lifestyle Intervention or Placebo in the Diabetes Prevention Program Outcomes Study (DPPOS).

Authors

Carrie L Pistenmaa, Lindsay Doherty, Emilia A Hermann, Angela L Brown, Dana Dabelea, Fernando Holguin, Karol Watson, William C Knowler, Marinella Temprosa, R Graham Barr, DPP Research Group

Published in

Respiratory medicine. Pages 109077. Aug 04, 2026. Epub Aug 04, 2026.

Abstract

Metformin and physical activity have been suggested as beneficial for chronic lung disease; however, there are no prior randomized trials.
The Diabetes Prevention Program (DPP) was a 3-year trial that randomized 3,234 individuals at risk for diabetes to metformin, lifestyle intervention or placebo. After the DPP, 88% of participants enrolled in the DPP Outcomes Study that offered lifestyle intervention to all and open-label continuation of metformin. Spirometry was performed at approximately 19 and 22 years post-randomization. Lung function measures were compared in an intention-to-treat (ITT) analysis by original randomization group. Models were unadjusted and adjusted for demographics, body size, smoking and sitting/standing at spirometry. Additional analyses tested prevalence of obstruction (FEV₁/FVC <70%), restrictive pattern (FVC 1/FVC ≥70%), preserved ratio impaired spirometry (PRISm: FEV₁ <80% predicted, FEV₁/FVC ≥70%) and symptoms (COPD Assessment Test [CAT] score ≥10).
The 1,888 participants with spirometry were a mean (±SD) age of 68.2±9.3 years, 70% female and 6% currently smoked and 33% had previously smoked cigarettes. Mean follow-up time was 19.0±0.8 years. The mean FEV₁ was 2.14±0.60 L, FVC 2.74±0.74 L, FEV₁/FVC 78.4±6.4%, mean BMI was 32.4±6.7 kg/m² and 58% had diabetes. In both unadjusted and adjusted ITT analyses, randomization group was not associated with FEV₁, FVC or FEV₁/FVC. Likewise, rates of obstruction, restrictive pattern, PRISm or symptoms did not differ by randomization group.
In this long-term follow-up after a randomized trial, we found no significant associations between randomization to metformin or lifestyle intervention and lung function or respiratory symptoms.

PMID:
42551713
Bibliographic data and abstract were imported from PubMed on 05 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.